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ABSTRACT 
 
Objective: To assess the relative cost effectiveness of moxifloxacin once-daily 
empirical monotherapy and ofloxacin/ metronidazole twice daily combination therapy 
for the treatment of uncomplicated pelvic inflammatory disease in adult female 
patients. 
 
Design: This is a retrospective cost analysis using data from a clinical trial in order to 
perform the economic anlysis from a funder perspective. The cost analysis is based on 
the clinical results of the MAIDEN study which is a prospective, randomized, double-
blind, multicentre, multinational Phase III study comparing the efficacy and safety of 
moxifloxacin 400 mg po od for 14 days with ofloxacin 400mg po bid plus 
metronidazole 400mg po bid for 14 days in patients with uncomplicated pelvic 
inflammatory disease. Decision analysis is used to characterise the economic 
outcomes between groups and provide a structure upon which to base the sensitivity 
analyses. Published 2004 cost values are used throughout. Cost values for 
moxifloxacin are based on the retail price of Avelon tablets in South Africa as appears 
on the Orderwise Retail Pharmacy Ordering System (September 2004). Cost values 
for the comparator, ofloxacin and metronidazole, are based on the cheapest available 
generics on the South African market i.e.  Zanocin 400 and Metazol 400mg 
respectively. 
 
Method: The cost analysis is based on the clinical results obtained from the 
MAIDEN study.  Patients were enrolled in either the moxifloxacin treatment group 
(Group A) or the ofloxacin / metronidazole comparator group (Group B). Resource 
utilization included: 
- cost for study antimicrobials (total number of doses for the study period) 
- treatment for adverse events occurring up to 7 days after stopping the study 
medication 
- treatment for failures (includes patients continued on antimicrobial therapy 
after the 14 day course of therapy) 
- cost of additional physician visits to treat adverse events and treatment failures 
The primary end-point is the overall cost of treatment per patient as determined by:  
iv 
Clinical response 7 to 14 days after the last dose of study medication (Test-of-Cure 
visit) 
 
Since the clinical findings from the MAIDEN study showed that moxifloxacin 
treatment was at least as efficacious as ofloxacin/metronidazole treatment, a cost-
minimization analysis was performed and the results were analysed according to 
decision analysis. Decision analysis was used to characterise the economic outcomes 
between the groups and provided a structure upon which to base the sensitivity 
analyses. The outcomes were depicted on a decision tree which proportionately 
determined the cost of treatment per patient in the two treatment groups. 
  
Results: 
No significant differences in clinical success rates were detected. Differences were 
mainly due to the cost of treating adverse events in the two groups. Costs per patient 
in the monotherapy vs combination therapy comparisons were R10 847.00 for 
moxifloxacin and R16 630.00 for ofloxacin/metronidazole treatment. Sensitivity 
analyses revealed that moxifloxacin monotherapy can be cost effective compared with 
ofloxacin/metronidazole combination therapy in different situations. 
 
Conclusion: 
Per patient, the cost of drug treatment and treatment of adverse events and clinical 
relapses was R10 847.00 for treatment with moxifloxacin therapy and R16 630.00 for 
ofloxacin/metronidazole therapy . In comparison to ofloxacin/metronidazole 
combination therapy, moxifloxacin monotherapy was therefore cost saving. 
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NOMENCLATURE 
 
bid: 
 
CI: 
 
Clinical Resolution 
 
 
 
Clinical Improvement 
 
 
 
Clinical Failure 
 
 
 
 
Indeterminate 
 
 
EDL: 
 
IV: 
 
MAIDEN 
 
 
 
 
 
od: 
Twice daily 
 
Confidence interval 
 
Disappearance of acute signs and symptoms of infection 
such that alternate antimicrobial therapy was not required 
or administered 
 
Improvement of acute signs and symptoms of infection 
such that alternate antimicrobial therapy was not required 
or administered 
 
No apparent response to therapy, persistence of signs and 
symptoms of infection, or reappearance of signs and 
symptoms at or before the test-of-cure visit, or use of 
additional antimicrobial therapy for the current infection 
 
Patients in whom clinical assessment was not possible to 
determine 
 
Essential Drugs List 
 
Intravenous 
 
Prospective, randomized, double-blind, multicentre, 
multinational study comparing efficacy and safety of 
moxifloxacin 400 mg po od for 14 days with ofloxacin 400 
mg po bid plus metronidazole 400 mg po bid for 14 days in 
patients with uncomplicated pelvic inflammatory disease 
 
Once daily 
xi 
 Perspective 
 
 
PID: 
 
po: 
 
SEP: 
 
TOC: 
 
 
WHO: 
 
 
of the analysis is the viewpoint from which the analysis is 
conducted and costs are measured 
 
Pelvic Inflammatory Disease 
 
per os 
 
Single Exit Price 
 
Test-of-Cure i.e. clinical response 7 to 14 days after last 
dose of study medication 
 
World Health Organisation 
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PREFACE 
 
The government of South Africa clearly outlines its commitment to ensuring 
availability and accessibility of medicines for all people in the health objectives of the 
National Drug Policy. The criteria for selection of essential drugs for Primary Health 
Care in South Africa are based on the WHO guidelines for a national EDL (Essential 
Drugs List) which includes the following points : 
• Sufficient proven scientific data regarding effectiveness must be available. 
• Any drug included in the EDL should have a substantial safety and risk/benefit 
ratio 
• Combination products, as an exception, will be included where patient compliance 
becomes an important factor, or two pharmacologically active ingredients are 
synergistically active in a product. 
• Where drugs are clinically equally effective, the drugs will be compared on the 
following factors: 
- The best cost advantage. 
- The best researched. 
- The best pharmacokinetic properties. 
- The best patient compliance. 
- The most reliable local manufacturer. 
 
In the context of the above principles, a pharmacoeconomic analysis is necessary for 
evaluating medicines in South Africa. Internationally, assessing new drug therapies 
for their cost effectiveness is becoming standard in an increasing number of countries. 
In addition to Australia, Canada and several other countries, the Netherlands and 
Finland have also recently taken steps in the direction of introducing 
pharmacoeconomic guidelines within a formal evidence-based decision making 
mechanism. A full cost-effectiveness analysis includes the following components:  
1. All relevant costs and clinical outcomes are included in the analysis and valued. 
2. The analysis is incremental in that it utilizes the difference in costs and difference 
in clinical outcomes between one specific pharmaceutical product as opposed to 
the other alternate therapy. 
3. Costs and clinical outcomes may be discounted over time if the outcome is long-
term. 
xiii 
4. The perspective of the decision-maker is clearly identified. The societal 
perspective that incorporates both direct and indirect costs and clinical outcomes 
should be presented. 
5. All sources of data for the baseline analysis are clearly identified. 
6. Sensitivity analyses are used to assess the robustness of the qualitative 
conclusions and identify areas where more research is needed to more precisely 
estimate the values of those variables to which the result is sensitive. 
7. The incremental cost-effectiveness ratios are compared with each in order to 
determine the relative economic attractiveness of investing in this pharmaceutical 
product as opposed to other healthcare interventions. A cost-effectiveness analysis 
is indicated when there are differences in efficacy and safety between two drugs 
for a specified indication. A cost effectiveness analysis should first assess whether 
the proposed drug is superior to current best practice from the available clinical 
trials. There is little value in assessing the cost effectiveness of a new drug when 
superiority has not been established. Where there is no difference in clinical 
outcomes, cost minimisation is used as a cost analysis tool. 
 
Pharmacoeconomics is therefore an integral part of formulary selection. The drug 
therapies used in this pharmacoeconomic analysis are those used in a clinical trial 
with its main focus on the private sector. They do not to date feature on the EDL. 
Within the framework of this pharmacoeconomic analysis, in order to establish the 
cost effectiveness of other drug therapies that do feature on the public sector’s EDL, 
additional studies that reflect the societal perspective would need to be performed. 
Pharmacoeconomics can not be used in isolation. Various factors play a role in the 
final decision. We hope that this study assists in providing a clearer vision of the 
value of pharmacoeconomics within the South African health structure as outlined in 
the treatment of uncomplicated pelvic inflammatory disease in the private sector with 
a focus on the fluoroquinolones and their use as monotherapy and combination 
therapy.  
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